MX2020001057A - Composiciones y metodos para tratar la galactosemia. - Google Patents

Composiciones y metodos para tratar la galactosemia.

Info

Publication number
MX2020001057A
MX2020001057A MX2020001057A MX2020001057A MX2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A
Authority
MX
Mexico
Prior art keywords
galactosemia
methods
treat
compositions
manifestations
Prior art date
Application number
MX2020001057A
Other languages
English (en)
Spanish (es)
Inventor
Shoshana Shendelman
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of MX2020001057A publication Critical patent/MX2020001057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020001057A 2017-07-28 2018-07-27 Composiciones y metodos para tratar la galactosemia. MX2020001057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538443P 2017-07-28 2017-07-28
PCT/US2018/044199 WO2019023648A1 (en) 2017-07-28 2018-07-27 COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA

Publications (1)

Publication Number Publication Date
MX2020001057A true MX2020001057A (es) 2020-11-24

Family

ID=65039851

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001057A MX2020001057A (es) 2017-07-28 2018-07-27 Composiciones y metodos para tratar la galactosemia.
MX2022015186A MX2022015186A (es) 2017-07-28 2020-01-27 Composiciones y metodos para tratar la galactosemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015186A MX2022015186A (es) 2017-07-28 2020-01-27 Composiciones y metodos para tratar la galactosemia.

Country Status (19)

Country Link
US (2) US11590131B2 (https=)
EP (2) EP4417260A3 (https=)
JP (3) JP7307059B2 (https=)
CN (3) CN119633117A (https=)
AU (2) AU2018307964B2 (https=)
CA (1) CA3071114A1 (https=)
DK (1) DK3658142T3 (https=)
ES (1) ES2983586T3 (https=)
FI (1) FI3658142T3 (https=)
HR (1) HRP20240840T1 (https=)
HU (1) HUE067079T2 (https=)
IL (2) IL272246B2 (https=)
LT (1) LT3658142T (https=)
MX (2) MX2020001057A (https=)
PL (1) PL3658142T3 (https=)
PT (1) PT3658142T (https=)
SG (1) SG11202000730QA (https=)
SI (1) SI3658142T1 (https=)
WO (1) WO2019023648A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) * 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
JP7457033B2 (ja) * 2019-02-28 2024-03-27 石薬集団中奇制薬技術（石家庄）有限公司 アルドース還元酵素阻害剤の塩、及びその製造方法と使用
CN113840825A (zh) * 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
WO2020227430A1 (en) 2019-05-07 2020-11-12 University Of Miami Treatment and detection of inherited neuropathies and associated disorders
CA3153108A1 (en) * 2019-10-08 2021-04-15 Riccardo Perfetti Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
IL297779A (en) * 2020-05-01 2022-12-01 Applied Therapeutics Inc Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025219948A1 (en) * 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
ES2032749T3 (es) 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
AU7386887A (en) 1986-06-12 1987-12-17 American Home Products Corporation Method of stimulating the immune system with tolrestat;(n-((5 -(trifluoromethyl)-6-methoxy-1-naphthenyl)thioxomethyl)-n-me hylglycine)
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
CA1307537C (en) * 1987-12-23 1992-09-15 Jay E. Wrobel N-naphthoylglycines as aldose reductase inhibitors
WO1989006651A1 (en) 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5728704A (en) 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
EP0847379A1 (en) 1995-08-28 1998-06-17 American Home Products Corporation Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
YU49315B (sh) 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
WO1999015529A1 (en) 1997-09-23 1999-04-01 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
CA2383983C (en) 1998-03-31 2009-09-29 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
AP2005003199A0 (en) 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
JP4511655B2 (ja) 1999-08-25 2010-07-28 ユニチカ株式会社 ソルビトール脱水素酵素、それを産生する微生物およびその製造方法
US6916824B1 (en) 1999-11-12 2005-07-12 Kansas State University Research Foundation Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
CA2442476A1 (en) 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
WO2003061660A1 (en) 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
CA2489470A1 (en) 2002-06-14 2003-12-24 Takeda Pharmaceutical Company Limited Prodrug and process for producing the same
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
JP5044122B2 (ja) * 2003-10-24 2012-10-10 株式会社明治 後期糖化最終生成物形成の新規阻害剤及びアルドース還元酵素阻害剤
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US20110092566A1 (en) 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
SI2137217T1 (sl) 2007-04-05 2014-07-31 Morphotek, Inc. Postopki za inhibiranje vezave endosialina na ligande
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US20100215726A1 (en) 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
WO2011037985A1 (en) 2009-09-23 2011-03-31 The Trustees Of The University Of Pennsylvania Aminothienopyridazine inhibitors of tau assembly
EP2502079B1 (en) 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
EP3192796B1 (en) 2010-07-16 2019-09-04 The Trustees of Columbia University in the City of New York Aldose reductase inhibitors and uses thereof
WO2012138384A1 (en) 2010-11-15 2012-10-11 U.S. Army Medical Research And Materiel Command Field sampling kit and methods for collecting and detecting alkyl methylphosphonic acids
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
WO2013123403A1 (en) 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
GB201205739D0 (en) 2012-03-30 2012-05-16 Ucl Business Plc Treatment of acute inflammation in the respiratory tract
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
US20170362237A1 (en) 2016-06-17 2017-12-21 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
EP2967339B1 (en) 2013-03-15 2019-11-20 Biogen MA Inc. Assessment of labeled probes in a subject
JP6187364B2 (ja) 2014-03-31 2017-08-30 ブラザー工業株式会社 印刷装置
JP6500992B2 (ja) 2015-09-01 2019-04-17 株式会社村田製作所 コイル内蔵部品
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
DK3352754T3 (da) 2016-06-21 2020-12-07 Univ Columbia Aldosereduktaseinhibitorer og fremgangsmåder til anvendelse deraf
JP2019535265A (ja) 2016-11-14 2019-12-12 メモリアル スローン ケタリング キャンサー センター 幹細胞由来シュワン細胞
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018200258A1 (en) 2017-04-27 2018-11-01 Applied Therapeutics Inc. Aldose reductase inhibitors and uses thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection
CA3110162A1 (en) 2018-08-20 2020-02-27 Maggie's Pearl, Llc Methods for treating congenital disorders of glycosylation
US20220071880A1 (en) 2019-02-12 2022-03-10 Applied Therapeutics, Inc. Methods for treating cutaneous aging
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
WO2020227430A1 (en) 2019-05-07 2020-11-12 University Of Miami Treatment and detection of inherited neuropathies and associated disorders
CA3153108A1 (en) 2019-10-08 2021-04-15 Riccardo Perfetti Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
IL297779A (en) 2020-05-01 2022-12-01 Applied Therapeutics Inc Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Also Published As

Publication number Publication date
RU2020107188A3 (https=) 2022-04-13
US20230346782A1 (en) 2023-11-02
JP2024159794A (ja) 2024-11-08
JP2020528938A (ja) 2020-10-01
EP4417260A2 (en) 2024-08-21
JP2022188305A (ja) 2022-12-20
PT3658142T (pt) 2024-06-27
EP3658142B1 (en) 2024-04-17
US11590131B2 (en) 2023-02-28
FI3658142T3 (fi) 2024-07-15
JP7307059B2 (ja) 2023-07-11
CN119633117A (zh) 2025-03-18
AU2018307964B2 (en) 2023-11-16
SG11202000730QA (en) 2020-02-27
EP3658142A1 (en) 2020-06-03
LT3658142T (lt) 2024-07-25
CN119971038A (zh) 2025-05-13
RU2020107188A (ru) 2021-08-30
DK3658142T3 (en) 2024-06-24
BR112020001755A2 (pt) 2020-07-21
ES2983586T3 (es) 2024-10-23
IL322622A (en) 2025-10-01
SI3658142T1 (sl) 2024-09-30
EP4417260A3 (en) 2024-11-20
IL272246A (en) 2020-03-31
MX2022015186A (es) 2023-01-24
US20200230139A1 (en) 2020-07-23
CN111065392A (zh) 2020-04-24
CA3071114A1 (en) 2019-01-31
AU2018307964A1 (en) 2020-02-13
IL272246B1 (en) 2025-09-01
CN111065392B (zh) 2024-10-25
EP3658142A4 (en) 2021-06-09
WO2019023648A1 (en) 2019-01-31
AU2024200537A1 (en) 2024-02-15
HRP20240840T1 (hr) 2024-10-11
IL272246B2 (en) 2026-01-01
JP7541064B2 (ja) 2024-08-27
PL3658142T3 (pl) 2024-08-26
HUE067079T2 (hu) 2024-09-28

Similar Documents

Publication Publication Date Title
MX2020001057A (es) Composiciones y metodos para tratar la galactosemia.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
PL3679141T3 (pl) Metody i kompozycje do hamowania ekspresji ldha
IL261015B (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
UY37018A (es) Inhibidores bicíclicos de pad4
AU2016263598A8 (en) Methods and kits for treating depression
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
BR112017006664A2 (pt) terapias de combinação
UY37017A (es) Inhibidores aza-bencimidazol de pad4
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
BR112018007021A2 (pt) compostos, composições e métodos para modulação de cftr
MX2020000367A (es) Inhibidores de rad51.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2017002238A1 (es) Método de tratamiento con tradipitant
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
IL281742A (en) Novel compounds as nadph oxidase inhibitors
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
IL286832A (en) Inhibitors of aldose reductase
DK3204037T3 (da) Sammensætninger og kits til enzymatisk debridering og fremgangsmåder til anvendelse deraf
EP3600451A4 (en) MEANS FOR STEM CELL DIFFERENTIATION AND CANCER TREATMENT